Pharmaceutical

SpliceBio secures $135m for gene therapy development

SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.

Jun 13, 2025 - 06:00
SpliceBio secures $135m for gene therapy development
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.
Read the original article

Tags:

Previous Article

FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market

STAT+: After late start, Eli Lilly has the momentum in ...

Jun 28, 2023

Opinion: What Rosalynn Carter understood about mental health

Opinion: What Rosalynn Carter understood about mental h...

Nov 21, 2023

Defender’s plans for motion sickness nasal gel stop with FDA rejection

Defender’s plans for motion sickness nasal gel stop wit...

Jan 31, 2024